Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Adams

Physician Assistant, Medical Billings, MT Physician Assistant

NPI 1982258190 CMS profile 8798079

2800 10Th Ave N, Billings, MT 59101

Open in the dashboard

General payments

$3,553

106 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Adams of Billings, MT is reported in the CMS Open Payments database as having received $3,553 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $399 19
2024 General $737 35
2023 General $624 32
2022 General $253 15
2021 General $1,542 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Adams
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Ashley Adams were reported at $399. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Ashley Adams Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,542 $156 $41–$563 $132
2022 $253 $185 $55–$649 $149
2023 $624 $199 $58–$717 $160
2024 $737 $206 $62–$740 $164
2025 $399 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. LivaNova USA, Inc. $1,542 5 payments
  2. AbbVie, Inc. $416 28 payments
  3. UCB, Inc. $174 6 payments
  4. Argenx US, Inc. $160 7 payments
  5. SK Life Science, Inc. $155 6 payments
  6. Ironshore Pharmaceuticals Inc. $116 9 payments
  7. Pfizer Inc. $116 6 payments
  8. Lilly USA, LLC $94 5 payments
  9. Alexion Pharmaceuticals, Inc. $82 3 payments
  10. Otsuka America Pharmaceutical, Inc. $69 3 payments
  11. Other $629 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,273 103 payments
  2. Travel and Lodging $1,280 3 payments
Products named General payments · program years 2021–2025
  1. VNS - Sentiva $1,542 5 payments
  2. UBRELVY $250 16 payments
  3. QULIPTA $240 14 payments
  4. JORNAY PM $116 9 payments
  5. NURTEC ODT $116 6 payments
  6. BOTOX $114 9 payments
  7. Fintepla $108 4 payments
  8. ZAVZPRET $98 5 payments
  9. VYVGART $82 4 payments
  10. VYVGART Hytrulo $78 3 payments
  11. Other $1,201 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,048

Median for Physician Assistant: 241

Drug cost

$109,544

Median for Physician Assistant: $4,110

Branded share of claims

19.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 30 $30,498
Emgality Pen Galcanezumab-Gnlm Brand 27 $18,272
Aimovig Autoinjector Erenumab-Aooe Brand 14 $15,224
Sumatriptan Succinate Generic 65 $13,326
Rasagiline Mesylate Generic 13 $5,872
Gabapentin Generic 133 $3,064
Levetiracetam Generic 62 $2,569
Eletriptan Hbr Eletriptan Hydrobromide Brand 14 $2,540
Duloxetine Hcl Generic 86 $2,481
Baclofen Generic 33 $2,268

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$93,981

Of which drugs: $57,894

Medicare patients

243

Average age 74

Services billed

13,077

138 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 54%
High blood pressure 52%
Depression 34%
Osteoporosis 23%
Ischemic heart disease 21%
COPD 18%
Chronic kidney disease 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 23 12,600 $57,892

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $71
$71 — —
UBRELVY
  • AbbVie, Inc. $54
$54 — —
Fintepla
  • UCB, Inc. $51
$51 — —
Hizentra
  • CSL Behring $44
$44 — —
Nayzilam
  • UCB, Inc. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record